Sage Therapeutics is open to a collaboration on its experimental drug for Huntington’s disease, Sage CEO Barry Greene said during an interview with Bloomberg. “We’ve had a lot of inbound interest” in the drug, called dalzanemdor, the executive is quoted by Bloomberg’s Madison Muller and Robert Langreth as having said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Novel Postpartum Depression Treatment Offers Upside Potential for Sage Therapeutics (NASDAQ:SAGE)
- Sage Therapeutics price target lowered to $25 from $28 at H.C. Wainwright
- Sage Therapeutics price target lowered to $15 from $26 at RBC Capital
- Sage Therapeutics price target lowered to $17 from $21 at Canaccord
- Sage Therapeutics price target lowered to $18 from $20 at Mizuho